معرفی
Lao Saal is a Senior Lecturer and Principal Investigator at Lund University Cancer Centre (LUCC), Lund University. They serve as Head of the Translational Oncogenomics Unit and hold multiple leadership roles including Project Manager and Supervisor within the cancer research ecosystem at Lund.
Dr. Saal's research focuses on translating innovative cancer genomics, liquid biopsies, and insights on PTEN/PI3K/AKT signaling into new clinical applications. Their work applies genome-wide technologies to study breast cancer biology with particular attention to circulating tumor DNA (ctDNA) as a biomarker. The research program aims to discover genomic aberrations in breast tumors, understand their clinical implications, develop targeted therapeutic approaches, and validate biomarker assays for therapy selection and monitoring residual disease.
With 95 research outputs spanning articles, meeting abstracts, book chapters, and reviews, Dr. Saal's work demonstrates consistent contributions to cancer genomics and biomarker development. The research portfolio shows a progression from fundamental genomic characterization toward clinical translation, with increasing focus on liquid biopsy applications and multi-modal profiling approaches.
Dr. Saal has secured significant research funding from Mrs. Berta Kamprad's Cancer Foundation, Cancerfonden, and Gyllenstiernska Krapperupsstiftelsen. They have supervised multiple research projects and are actively engaged in academic service, having organized numerous workshops, seminars, and conferences related to cancer research. Current projects include the Sweden Canceromics Analysis Network - Breast (SCAN-B) initiative and research on ctDNA for patient stratification.
As part of the Canceromics Branch at LUCC, Dr. Saal collaborates extensively with clinical oncologists, surgeons, and pathologists, and participates in international collaborations. Their research contributes to Sustainable Development Goals related to health and well-being through advancements in cancer diagnostics and personalized treatment approaches.
